Sökning: id:"swepub:oai:DiVA.org:uu-150361" >
Integrating Efficac...
Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications
-
- Haglund, Caroline, 1981- (författare)
- Uppsala universitet,Klinisk farmakologi
-
- Lindhagen, Elin, Docent (preses)
- Uppsala universitet,Klinisk farmakologi
-
- Larsson, Rolf, Professor (preses)
- Uppsala universitet,Klinisk farmakologi
-
visa fler...
-
- Åleskog, Anna, Docent (preses)
- Uppsala universitet,Klinisk farmakologi
-
- Vitols, Sigurd, Adjungerad Professor (opponent)
- Karolinska Institutet, Klinisk Farmakologi
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789155480516
- Uppsala : Acta Unversitatis Upsaliensis, 2011
- Engelska 53 s.
-
Serie: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1651-6206 ; 665
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. A high correlation was seen when comparing the 50% inhibitory concentrations (IC50) from FMCA-GM with the IC50 from the established clonogenic assay (CFU-GM). In paper II, FMCA-GM was complemented with additional cell models, establishing a normal cell panel. In vitro toxicity towards the five normal cell types was compared with known clinical adverse event profiles. The normal cell panel roughly reflected the tissue specific toxicities but was most useful in the prediction of therapeutic index. In paper III the use of peripheral blood lymphocytes from human, dog, rat and mouse to detect species differences in cellular drug sensitivity was described. Good agreement between our method and the established CFU-GM assay was observed. In paper II the benefit of using primary tumour cells from patients to predict cancer diagnosis-specific activity was studied. The in vitro activity of fourteen anticancer drugs was tested in tumour samples of both haematological and solid tumour origin. In general, clinical activity was well reflected. In paper IV, the efficacy and toxicity models were applied for experimental follow-up of a novel inhibitor of the ubiquitin-proteasome system, CB3 (Phosphoric acid, 2,3-dihydro-1,1-dioxido-3-thienyl diphenyl ester). In the preliminary characterization of CB3, antitumour activity and a favourable toxicity profile were displayed, although the exact mechanism of action remains to be elucidated. CB3 will therefore be further investigated. In conclusion, the work presented here contributes to different parts of the preclinical drug development and the methods may aid in the characterization of anticancer compounds
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Nyckelord
- Anticancer drugs
- In vitro assays
- Toxicity testing
- Haematological toxicity
- Primary tumour cells
- Species difference
- Clinical pharmacology
- Klinisk farmakologi
- Clinical Pharmacology
- Klinisk farmakologi
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas